VYGR · Voyager Therapeutics, Inc.

$3.07 +0.03 (+0.82%)

Market Cap

$183.68M

60.42M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Alfred Sandrock	CEO	$674,903	—	$611,900	$843,900	$361,917	$15,750	$2,508,370
Jacquelyn Fahey Sandell	Former Chief Legal Officer	$297,842	—	$175,130	$241,530	—	$760,484	$1,474,986
Robin Swartz	COO	$520,190	—	$300,675	$414,675	$205,475	$13,285	$1,454,300
Toby Ferguson	Chief Medical Officer	$513,369	—	$265,860	$366,660	$202,781	$15,750	$1,364,420

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Alfred Sandrock	CEO	$652,080	—	$988,000	$1,372,800	$351,471	$15,525	$3,379,876
Toby Ferguson	Chief Medical Officer	$363,750	—	$1,106,700	$1,333,500	$148,159	$14,688	$2,966,797
Robin Swartz	COO	$490,745	—	$380,000	$528,000	$199,534	$15,525	$1,613,804
Jacquelyn Fahey Sandell	Former Chief Legal Officer	$468,758	—	$235,600	$327,360	$185,066	$15,525	$1,232,309

Executive changes

Person	Role	Change	Effective	Filed
Amy Quinlan	principal accounting officer	Appointed	2026-05-08	2026-04-21
Nathan Jorgensen, Ph.D.	Chief Financial Officer	Resigned	2026-05-08	2026-04-21
Toby Ferguson, M.D., Ph.D.	Chief Medical Officer	Resigned	2026-02-20	2026-02-12

Key facts CIK 1640266 CUSIP 92915B106 13F (30d) 22 filings 22 filers Visit website Investor relations